September 6, 2014
Web Version | Share with a colleague | eNews Subscribe
You are subscribed to the FormularyWatch eNews
FDA has approved pembrolizumab (Keytruda, Merck) for treatment of patients with advanced or unresetable melanoma who are no longer responding to other drugs. » Read more on this breakthrough drug
An investigational heart failure drug showed benefit in heart failure patients over ACE inhibitors or ARBs. » Here's the latest data from the European Society of Cardiology
#icymi
Editorial Questions? Contact the Editorial Team. Click Here. Sales, Reprints, Classified questions? Contact the Sales Team. Click Here.
